Zolgensma’s Pay Model Avoids Medicaid Best Price Pitfall

By John Wilkerson / May 30, 2019 at 2:57 PM
The pay model for the world’s most expensive drug, Zolgensma, lets insurers pay less for the gene therapy when it doesn’t work without triggering Medicaid best price, a policy that has frustrated development of value-based pay arrangements, said a spokesperson for Zolgensma’s maker AveXis. The Zolgensma pay model is unique, but it could be applied to other expensive gene therapies, according to a spokesperson for Accredo, which developed the pay model. FDA approved Zolgensma last week, and the Novartis company...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.